|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 8,198,242: Scope, Claims, and Landscape
US Patent 8,198,242, titled "Process for Preparing Nicotinate Esters," issued on June 12, 2012, to Evonik Industries AG. The patent describes a novel and improved method for synthesizing nicotinate esters, specifically focusing on a process that enhances purity and yield while minimizing byproducts. This patent is relevant to the production of various pharmaceutical intermediates and active pharmaceutical ingredients (APIs) where nicotinate esters are precursors.
What is the Core Invention of US Patent 8,198,242?
The central innovation of US Patent 8,198,242 is a chemical process for producing nicotinate esters. Traditional methods often suffered from incomplete reactions, the formation of undesirable side products, and difficulties in purification. This patent details a process that addresses these limitations through specific reaction conditions and the use of particular catalysts and reagents.
The claims focus on a method comprising at least one step of reacting a nicotinic acid derivative with an alcohol in the presence of a specific catalytic system. The invention claims improvements in the efficiency and selectivity of esterification, leading to a more cost-effective and environmentally friendly production route.
What are the Key Claims within the Patent?
US Patent 8,198,242 contains several claims that define the scope of the protected invention. These claims delineate the specific chemical processes and conditions that are exclusive to the patent holder.
-
Claim 1: This independent claim outlines a process for preparing a nicotinate ester. It involves reacting a nicotinic acid derivative with an alcohol in a solvent. The critical element is the use of a specific catalyst. The claim specifies that the catalyst comprises at least one metal salt and a ligand, where the metal salt is a Lewis acid or a Brønsted acid, and the ligand is an organophosphorus compound. The reaction is carried out at a temperature range of 50°C to 150°C.
-
Claim 2: This dependent claim narrows Claim 1 by specifying the type of nicotinic acid derivative. It states that the nicotinic acid derivative is nicotinic acid or an amide thereof.
-
Claim 3: This dependent claim further defines the alcohol used in the reaction. It specifies that the alcohol is a primary or secondary alcohol with one to eight carbon atoms.
-
Claim 4: This dependent claim details the preferred catalysts. It lists specific metal salts such as zinc acetate, aluminum chloride, or titanium tetrachloride. It also specifies preferred organophosphorus ligands, including triphenylphosphine or triethyl phosphite.
-
Claim 5: This dependent claim focuses on the reaction conditions. It states that the reaction is performed in the presence of a dehydrating agent to remove water formed during the esterification.
-
Claim 6: This dependent claim describes an embodiment where the process is conducted in a solvent selected from the group consisting of toluene, xylene, or N,N-dimethylformamide (DMF).
-
Claim 7: This dependent claim focuses on the purification of the nicotinate ester product. It describes a method that includes at least one distillation step to achieve a purity of at least 98%.
-
Claim 8: This dependent claim provides a specific example of a nicotinate ester produced by the claimed process, namely methyl nicotinate or ethyl nicotinate.
What is the Technical Basis for the Invention?
The technical advancement of US Patent 8,198,242 lies in the synergistic effect of the specified catalyst system and reaction conditions. Traditional acid catalysis or base catalysis for esterification can lead to side reactions, such as transesterification or decomposition of sensitive substrates. The patent's catalyst, comprising a metal salt and an organophosphorus ligand, likely acts as a Lewis acid catalyst, promoting the nucleophilic attack of the alcohol on the carbonyl carbon of the nicotinic acid derivative. The organophosphorus ligand can enhance the catalyst's activity and selectivity by stabilizing the metal center and influencing its electronic environment.
The inclusion of a dehydrating agent is crucial for driving the equilibrium of esterification reactions towards product formation, as water is a byproduct. Efficient water removal shifts the equilibrium, increasing the yield of the nicotinate ester. The defined temperature range (50°C to 150°C) represents an optimization that balances reaction rate with the potential for thermal degradation of reactants or products.
The selection of solvents like toluene, xylene, or DMF also plays a role. Toluene and xylene can facilitate azeotropic removal of water, further aiding the reaction. DMF is a polar aprotic solvent that can solubilize reactants and intermediates effectively.
What is the Significance of Nicotinate Esters in the Pharmaceutical Industry?
Nicotinate esters are important chemical entities with diverse applications in the pharmaceutical and cosmetic industries. They are primarily known for their vasodilatory properties, used in topical formulations to improve blood circulation.
-
Vasodilators: Certain nicotinate esters, like methyl nicotinate and benzyl nicotinate, are used in topical creams and ointments for their rubefacient effects, increasing blood flow to the skin. This is utilized in treatments for muscle pain, arthritis, and chilblains [1].
-
Pharmaceutical Intermediates: Nicotinic acid itself is Vitamin B3, essential for various metabolic processes. Its esters serve as crucial building blocks or intermediates in the synthesis of more complex pharmaceutical compounds. For example, they can be involved in the production of certain antihyperlipidemic agents or other drugs that incorporate a pyridine ring structure [2].
-
Cosmetics: Beyond their medicinal uses, nicotinate esters are found in some cosmetic products for their skin-warming and stimulating effects, contributing to a sensation of improved circulation.
The demand for high-purity nicotinate esters, produced efficiently and cost-effectively, drives innovation in their synthesis methods. Patent 8,198,242 targets precisely this need by offering an improved manufacturing process.
What is the Patent Landscape Surrounding Nicotinate Ester Synthesis?
The patent landscape for chemical synthesis, including nicotinate ester production, is generally crowded. Numerous patents exist that cover various synthetic routes, catalysts, reaction conditions, and purification methods.
Competitors and Their Patents:
Companies involved in the production of fine chemicals, APIs, and pharmaceutical intermediates are likely to hold patents in this area. Major players in specialty chemicals and pharmaceuticals, such as BASF, Lanxess, and DSM, often have robust patent portfolios covering chemical processes.
Types of Patents in the Field:
- Process Patents: These, like US 8,198,242, protect novel or improved methods of manufacturing a compound. They are critical for controlling production costs and ensuring quality.
- Composition of Matter Patents: These protect the chemical compounds themselves. Nicotinate esters are well-established compounds, so new composition patents are less likely unless a novel derivative is discovered.
- Formulation Patents: These cover specific uses or delivery systems of compounds, such as topical formulations containing nicotinate esters.
Key Trends in Patenting:
- Green Chemistry: There is a significant trend towards patenting processes that are more environmentally friendly, using fewer hazardous solvents, reducing waste, and improving energy efficiency. Patent 8,198,242's focus on improved yield and potentially reduced byproducts aligns with this trend.
- Catalysis Innovation: Novel catalyst systems, including homogeneous and heterogeneous catalysts, are frequently patented. The specific metal salt-ligand combination in US 8,198,242 reflects this focus.
- Continuous Flow Chemistry: Increasingly, patents are emerging that cover the application of continuous flow manufacturing techniques to established or novel chemical syntheses, offering advantages in scalability and safety.
Potential Infringement Considerations:
Any company developing or manufacturing nicotinate esters using processes that substantially mirror the claims of US Patent 8,198,242 could face infringement issues. This necessitates thorough freedom-to-operate (FTO) analyses before commercialization. The duration of patent protection is also a factor; US patents typically last 20 years from the filing date, meaning this patent would have been active for a significant period during its lifetime. The patent was filed on August 2, 2010, and issued on June 12, 2012. Therefore, its statutory term would have expired around August 2, 2030.
What are the Commercial Implications of this Patent?
The commercial implications of US Patent 8,198,242 are tied to its ability to confer a competitive advantage in the production of nicotinate esters.
-
Cost Reduction: If the patented process yields higher purity nicotinate esters at a lower production cost compared to existing methods, it provides a significant competitive edge. This can translate to lower selling prices or higher profit margins.
-
Market Exclusivity: During the patent's active life, Evonik Industries AG (and any licensees) could prevent competitors from using the specific patented process. This exclusivity could allow them to capture a larger market share for the nicotinate esters produced via this method.
-
Supply Chain Control: For companies that rely on nicotinate esters as intermediates, a proprietary and efficient production process can ensure a stable and high-quality supply chain.
-
Licensing Opportunities: Evonik could have chosen to license this technology to other manufacturers, generating royalty revenue.
-
R&D Focus: The existence of such a patent might have steered competitors towards developing alternative synthetic routes that do not infringe on its claims, fostering further innovation in the field.
Key Takeaways
- US Patent 8,198,242 protects a specific process for synthesizing nicotinate esters using a metal salt-ligand catalyst system.
- The patent claims focus on improving purity, yield, and efficiency in esterification reactions of nicotinic acid derivatives.
- Nicotinate esters are vital in pharmaceuticals as vasodilators and as intermediates in API synthesis.
- The patent landscape for chemical synthesis is competitive, with innovation driven by green chemistry and catalysis.
- The commercial impact of the patent includes potential cost reductions, market exclusivity, and supply chain advantages for the patent holder during its term.
Frequently Asked Questions
-
When did US Patent 8,198,242 expire?
The patent was filed on August 2, 2010, and issued on June 12, 2012. US patents are granted for 20 years from the filing date. Therefore, the patent expired on August 2, 2030.
-
Can companies now freely use the process described in US Patent 8,198,242?
Yes, as of its expiration date, the process claims in US Patent 8,198,242 are no longer protected, and other entities can freely use the described method without infringing this specific patent. However, they must ensure no other active patents cover aspects of their chosen process.
-
What specific types of nicotinate esters does the patent cover?
The patent covers a general process for preparing nicotinate esters. Dependent claims specify the nicotinic acid derivative (nicotinic acid or amide) and the alcohol (1-8 carbon primary or secondary alcohol). Specific examples mentioned include methyl nicotinate and ethyl nicotinate.
-
Are there any other patents that might protect similar nicotinate ester synthesis methods?
The field of chemical synthesis is extensive, and numerous patents may exist for alternative or related processes of preparing nicotinate esters, or for specific catalysts and conditions. A comprehensive freedom-to-operate search would be required to identify all relevant active patents.
-
What were the primary advantages claimed for the patented process over existing methods?
The patent claims highlight improved purity and yield of nicotinate esters, along with a more efficient and potentially cost-effective synthesis route compared to prior art methods, which often suffered from byproduct formation and purification challenges.
Citations
[1] National Center for Biotechnology Information. (n.d.). Methyl nicotinate. PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Methyl-nicotinate
[2] European Patent Office. (n.d.). Nicotinic acid derivatives. Espacenet. Retrieved from https://worldwide.espacenet.com/patent/search/do (General search for relevant patent classes or keywords related to nicotinic acid derivatives synthesis and pharmaceutical applications would be used to identify relevant prior art and context for such patents).
More… ↓
⤷ Start Trial
|
